BIOTRACK FUND I GP, LP

The fund invests in the analytical testing, track-and-trace, and biosecurity infrastructure that cannabis regulators and producers are required to adopt. Rather than backing cultivation or retail companies, it targets the mandatory instrumentation and software layer — mass spectrometry, LIMS platforms, and pathogen screening — that supports government compliance mandates. This positions the portfolio to capture spending that is non-discretionary for licensed operators.

No. The vehicle has intentionally avoided equity positions in cultivation, processing, or dispensary operations. This structural choice isolates the fund from federal banking restrictions and IRS Section 280E tax treatment that affect plant-touching businesses, while still providing institutional investors exposure to the regulated cannabis supply chain through its infrastructure requirements.

The fund has historically focused on early-adopter cannabis markets in the United States and Canada where state or provincial regulations mandate accredited laboratory testing and seed-to-sale tracking. Its deployment follows regulatory rollouts — jurisdictions that require certified instrumentation and compliance data systems create the demand base for its portfolio companies.

The identities of the general partners or investment committee members are not publicly disclosed in available filings or official communications. As an emerging first-time fund with a niche thesis in the cannabis infrastructure space, the manager has maintained a low public profile, and no named investment leads have been reported in industry press.